Cynthia Schwalm to join Hikma's board
Hikma Pharmaceuticals soon will have a new member of its board of directors. The company announced the appointment of Cynthia Schwalm as an independent nonexecutive director effective June 1.
“I am very pleased that Cynthia will be joining the Hikma board. She brings extensive, proven experience in providing strong leadership through transformation,” executive chairman Darwazah Said said. “Her extensive commercial and leadership experience in the pharmaceutical and biotech industries, as well as her experience as a healthcare practitioner ,will bring a fresh perspective to the board and our next stage of growth.”
Most recently, Schwalm was president and CEO of the North American divisions of the global pharmaceutical companies Ipsen and Eisai. She also held leadership positions at Amgen and Johnson & Johnson. She is a nonexecutive director of Caladrius Biosciences, Kadman Group and G1 Therapeutics, where she chairs the compensation committee.
She also is a member of the National Association of Corporate Directors and an angel investment group associated with the University of North Carolina. For nearly a decade, she served on the Women’s Leadership Advisory Board at Harvard University’s Kennedy School of Government.
Schwalm has a Bachelor of Science in Nursing from the University of Delaware and Executive Master of Business Administration from Wharton at the University of Pennsylvania.
“I am very pleased that Cynthia will be joining the Hikma board. She brings extensive, proven experience in providing strong leadership through transformation,” executive chairman Darwazah Said said. “Her extensive commercial and leadership experience in the pharmaceutical and biotech industries, as well as her experience as a healthcare practitioner ,will bring a fresh perspective to the board and our next stage of growth.”Most recently, Schwalm was president and CEO of the North American divisions of the global pharmaceutical companies Ipsen and Eisai. She also held leadership positions at Amgen and Johnson & Johnson. She is a nonexecutive director of Caladrius Biosciences, Kadman Group and G1 Therapeutics, where she chairs the compensation committee.
She also is a member of the National Association of Corporate Directors and an angel investment group associated with the University of North Carolina. For nearly a decade, she served on the Women’s Leadership Advisory Board at Harvard University’s Kennedy School of Government.
Schwalm has a Bachelor of Science in Nursing from the University of Delaware and Executive Master of Business Administration from Wharton at the University of Pennsylvania.